Actualités

Shares of biopharmaceutical drug delivery company Halozyme Therapeutics (NASDAQ:HALO) jumped 18.1% in the afternoon session after the company reported strong second-quarter earnings that surpassed analyst expectations and raised its full-year financial guidance.

Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.

Halozyme's ENHANZE platform drives a 48% revenue surge, with new partnerships and Hypercon progress fueling a second growth engine.

Natera and Halozyme Therapeutics saw gains above 15%, led by bullish Wall Street commentary after better-than-expected second-quarter results.

Moby summary of Halozyme Therapeutics, Inc.'s Q2 2026 earnings call

Halozyme Therapeutics (NASDAQ:HALO) reported record second-quarter revenue and raised its full-year outlook, citing growth in royalty income from its ENHANZE drug-delivery platform, contributions from newer product launches and revenue from newly signed collaboration agreements. Total revenue rose

Although the revenue and EPS for Halozyme Therapeutics (HALO) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of +25.28% and +17.44%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ensuing tech selloff in 2022 will surely remember that the market’s punishment can be swift and severe when trajectories fall.

Halozyme Therapeutics is at a new high on Friday with earnings due on Aug. 6. Philip Morris International and KeyCorp are also at highs.

While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak competitive positioning.

Halozyme Therapeutics recently entered a global partnership and licence agreement with Incyte to apply its Enhanze drug delivery technology to additional subcutaneous formulations of INCA033989, a monoclonal antibody targeting mutant calreticulin in myeloproliferative neoplasms. This collaboration highlights how Halozyme can plug its Enhanze platform into emerging precision oncology assets, potentially broadening future royalty-bearing indications in blood cancers. We’ll now examine how this...

The companies aim to enable simplified dosing and delivery methods for patients receiving treatment for MPNs.

Halozyme Therapeutics (NASDAQ:HALO) has entered into a global collaboration and license agreement with Incyte (NASDAQ:INCY) to support the development of subcutaneous formulations of INCA033989, expanding the use of its ENHANZE® drug delivery technology into another partnered program. Key Investor TakeawaysHalozyme signed a global collaboration and license agreement with Incyte centered on ENHANZE® drug delivery technology.

Halozyme Therapeutics Inc. (NASDAQ:HALO) is one of the 8 Most Undervalued Growth Stocks to Buy for the Next 10 Years. On June 16, H.C. Wainwright analyst Mitchell Kapoor reiterated a Buy rating on Halozyme Therapeutics Inc. (NASDAQ:HALO) and assigned a target price of $95. The stock’s potential has been noticed by market participants, as evident […]

The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether these cheap assets are genuinely undervalued or simply on sale due to their potentially deteriorating business models.

Halozyme Therapeutics trades at $78.57 and has moved in lockstep with the market. Its shares have returned 8.5% over the last six months while the S&P 500 has gained 7.2%.

Each stock in this article is trading near its 52-week high. These elevated prices usually indicate some degree of investor confidence, business improvements, or favorable market conditions.

While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies — as Jeff Bezos said, “Your margin is my opportunity”.

Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

In recent days, Halozyme Therapeutics’ partner argenx reported positive new data for a therapy using Halozyme’s ENHANZE® drug delivery technology, while an analyst reaffirmed a positive rating on the company. This combination of external clinical validation and continued analyst support underscores how Halozyme’s business model is closely tied to partner success with its core platform. We’ll now examine how this fresh validation of ENHANZE® could influence Halozyme’s existing investment...

Shares of biopharmaceutical drug delivery company Halozyme Therapeutics (NASDAQ:HALO) jumped 5.2% in the afternoon session after an analyst reiterated a Buy rating on the stock, and a partner company, argenx, presented positive new data for a drug that utilizes Halozyme's technology.

Investing.com -- J.P. Morgan has reinstated coverage on 14 large-cap biotechnology companies, arguing the sector is entering a major inflection point as pipeline successes increasingly translate into profitable and diversified commercial businesses.

Myriad Genetics ramps up oncology launches in 2026 as Cancer Care Continuum growth and GeneSight reimbursement gains support revenue guidance.

Investors need to pay close attention to HALO stock based on the movements in the options market lately.

Halozyme Therapeutics stock snapshot after recent performance Halozyme Therapeutics (HALO) has drawn investor attention after a mixed recent run, with the stock up over the past month but down over the past 3 months, prompting a closer look at its fundamentals. See our latest analysis for Halozyme Therapeutics. Recent trading has been mixed, with a 30 day share price return of 4.53% but a 90 day share price return that is down 2.90%. In contrast, the 1 year total shareholder return of 25.27%...

Halozyme Therapeutics’ first quarter results for 2026 were met with a positive market response, underpinned by substantial royalty revenue growth and the expanding adoption of subcutaneous drug delivery through its ENHANZE technology. CEO Helen Torley credited the quarter’s momentum to broader use of key partner products such as DARZALEX, VYVGART Hytrulo, and PHESGO, with royalty streams up 43% year-over-year. The company also benefited from ramping contributions from recently launched therapies

Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ensuing tech selloff in 2022 will surely remember that the market’s punishment can be swift and severe when trajectories fall.

A number of stocks fell in the afternoon session after the April PPI report showed wholesale inflation accelerating to 6% annually, with service-sector prices rising at their fastest pace in four years.

The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Halozyme Therapeutics (NASDAQ:HALO) and the rest of the therapeutics stocks fared in Q1.